AcquisitionOther
EAGLE PHARMACEUTICALS, INC. acquired Acacia, adding two FDA-approved new chemical entities, BARHEMSYS ®
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
EAGLE PHARMACEUTICALS, INC. -> Acacia, adding two FDA-approved new chemical entities, BARHEMSYS ® · $3.1 billion
This investment brings a pipeline of three leading indications in which ENA-001, a novel agnostic respiratory stimulant, is the most advanced candidate, with the potential to come to market for post operative respiratory depression in 2026 and community drug o
Open source record (SEC) ↗